BACKGROUND: Cytochrome P450 2C19 is responsible for the metabolism of many drugs, including the activation of clopidogrel. The allele CYP2C19*17 is associated with ultra-rapid metabolizer phenotypes by increasing gene transcription. This study tests to what extent CYP2C19*17 enhances CYP2C19 expression in human liver and whether additional regulatory variants contribute to variation in CYP2C19 expression. METHODS: CYP2C19 mRNA was measured with quantitative real-time PCR (qRT-PCR), enzyme activity as metabolic velocity with S-mephenytoin as the substrate and allelic mRNA expression ratio with SNaPshot in human livers. CYP2C19 transcribed exons and a 4kb promoter region were sequenced using IonTorrent PGM or Sanger sequencing and screened for polymorphisms associated with total hepatic CYP2C19 mRNA, enzyme activity and allelic mRNA ratios. RESULTS: Livers heterozygote and homozygous for CYP2C19*17 had mRNA levels 1.8-fold (p=0.028) and 2.9-fold (p=0.006), respectively, above homozygous reference allele livers. CYP2C19*17 heterozygotes were also associated with increased allelic mRNA expression (allelic ratio ~1.8-fold, SD±0.6, p<0.005), whereas CYP2C19 enzyme activity was elevated 2.3-fold, with borderline significance (p=0.06) in CYP2C19*17 carriers. One liver sample of African ancestry displayed a 2-fold allelic expression ratio, and another sample, a ~12-fold increase in metabolic velocity. Neither case was accounted for by *17, which indicates the presence of additional regulatory variants. CONCLUSIONS: Our findings confirm *17 as a regulatory polymorphism enhancing hepatic CYP2C19 expression 2-fold with potential to compensate for the loss of function allele CYP2C19*2. Additional regulatory factors may also enhance CYP2C19 expression in African American populations.
BACKGROUND:Cytochrome P450 2C19 is responsible for the metabolism of many drugs, including the activation of clopidogrel. The allele CYP2C19*17 is associated with ultra-rapid metabolizer phenotypes by increasing gene transcription. This study tests to what extent CYP2C19*17 enhances CYP2C19 expression in human liver and whether additional regulatory variants contribute to variation in CYP2C19 expression. METHODS:CYP2C19 mRNA was measured with quantitative real-time PCR (qRT-PCR), enzyme activity as metabolic velocity with S-mephenytoin as the substrate and allelic mRNA expression ratio with SNaPshot in human livers. CYP2C19 transcribed exons and a 4kb promoter region were sequenced using IonTorrent PGM or Sanger sequencing and screened for polymorphisms associated with total hepatic CYP2C19 mRNA, enzyme activity and allelic mRNA ratios. RESULTS: Livers heterozygote and homozygous for CYP2C19*17 had mRNA levels 1.8-fold (p=0.028) and 2.9-fold (p=0.006), respectively, above homozygous reference allele livers. CYP2C19*17 heterozygotes were also associated with increased allelic mRNA expression (allelic ratio ~1.8-fold, SD±0.6, p<0.005), whereas CYP2C19 enzyme activity was elevated 2.3-fold, with borderline significance (p=0.06) in CYP2C19*17 carriers. One liver sample of African ancestry displayed a 2-fold allelic expression ratio, and another sample, a ~12-fold increase in metabolic velocity. Neither case was accounted for by *17, which indicates the presence of additional regulatory variants. CONCLUSIONS: Our findings confirm *17 as a regulatory polymorphism enhancing hepatic CYP2C19 expression 2-fold with potential to compensate for the loss of function allele CYP2C19*2. Additional regulatory factors may also enhance CYP2C19 expression in African American populations.
Authors: Klaus A Tiroch; Dirk Sibbing; Werner Koch; Tobias Roosen-Runge; Julinda Mehilli; Albert Schömig; Adnan Kastrati Journal: Am Heart J Date: 2010-09 Impact factor: 4.749
Authors: Guillaume Paré; Shamir R Mehta; Salim Yusuf; Sonia S Anand; Stuart J Connolly; Jack Hirsh; Katy Simonsen; Deepak L Bhatt; Keith A A Fox; John W Eikelboom Journal: N Engl J Med Date: 2010-08-29 Impact factor: 91.245
Authors: Jessica L Mega; Tabassome Simon; Jean-Philippe Collet; Jeffrey L Anderson; Elliott M Antman; Kevin Bliden; Christopher P Cannon; Nicolas Danchin; Betti Giusti; Paul Gurbel; Benjamin D Horne; Jean-Sebastian Hulot; Adnan Kastrati; Gilles Montalescot; Franz-Josef Neumann; Lei Shen; Dirk Sibbing; P Gabriel Steg; Dietmar Trenk; Stephen D Wiviott; Marc S Sabatine Journal: JAMA Date: 2010-10-27 Impact factor: 56.272
Authors: D Sibbing; D Gebhard; W Koch; S Braun; J Stegherr; T Morath; N Von Beckerath; J Mehilli; A Schömig; T Schuster; A Kastrati Journal: J Thromb Haemost Date: 2010-05-21 Impact factor: 5.824
Authors: Rasmus S Pedersen; Charlotte Brasch-Andersen; Sarah C Sim; Troels K Bergmann; Jónrit Halling; Maria S Petersen; Pál Weihe; Hege Edvardsen; Vessela N Kristensen; Kim Brøsen; Magnus Ingelman-Sundberg Journal: Eur J Clin Pharmacol Date: 2010-07-28 Impact factor: 2.953
Authors: Dirk Sibbing; Werner Koch; Daniela Gebhard; Tibor Schuster; Siegmund Braun; Julia Stegherr; Tanja Morath; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati Journal: Circulation Date: 2010-01-18 Impact factor: 29.690
Authors: A Ortega-Vázquez; P Dorado; I Fricke-Galindo; H Jung-Cook; N Monroy-Jaramillo; I E Martínez-Juárez; I Familiar-López; E Peñas-Lledó; A LLerena; M López-López Journal: Pharmacogenomics J Date: 2015-06-30 Impact factor: 3.550
Authors: Robin P Smith; Walter L Eckalbar; Kari M Morrissey; Marcelo R Luizon; Thomas J Hoffmann; Xuefeng Sun; Stacy L Jones; Shelley Force Aldred; Anuradha Ramamoorthy; Zeruesenay Desta; Yunlong Liu; Todd C Skaar; Nathan D Trinklein; Kathleen M Giacomini; Nadav Ahituv Journal: PLoS Genet Date: 2014-10-02 Impact factor: 5.917
Authors: Y Shirasaka; A S Chaudhry; M McDonald; B Prasad; T Wong; J C Calamia; A Fohner; T A Thornton; N Isoherranen; J D Unadkat; A E Rettie; E G Schuetz; K E Thummel Journal: Pharmacogenomics J Date: 2015-09-01 Impact factor: 3.245